|Bid||29.23 x 800|
|Ask||34.20 x 1200|
|Day's range||27.97 - 29.47|
|52-week range||15.58 - 68.65|
|Beta (5Y monthly)||1.14|
|PE ratio (TTM)||N/A|
|Earnings date||07 Nov 2022 - 11 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||50.57|
FRIENDSWOOD, Texas, September 23, 2022--Castle announced the publication of a study validating the performance of DecisionDx®-Melanoma’s proprietary algorithm, i31-ROR.
FRIENDSWOOD, Texas, September 21, 2022--Castle provided a proposed framework for use of its MyPath® Melanoma and DiffDx®-Melanoma tests to help achieve personalized management plans.
FRIENDSWOOD, Texas, September 20, 2022--Castle Biosciences will present the Company’s foundational guideposts and three-year financial targets during its Investor Day today.